What are the advantages of Takara Tet-On 3G systems?
What are the advantages of Takara Tet-On 3G systems?
When the Tet-On system was originally launched by Clontech Laboratories (now Takara Bio USA, Inc.) in 1996, it was the premier inducible expression system. However, its performance has been surpassed by two subsequent generations of the Tet-On system. Compared to their predecessors, Tet-On 3G systems demonstrate lower basal expression and higher sensitivity to the doxycycline (Dox) inducer.
1. Lowest basal expression
The PTRE3G promoter contains mutations that reduce background expression by 5–20 fold compared to our previous tightest promoter, PTight.
2. Highest sensitivity
The Tet-On 3G transactivator contains mutations that significantly increase its sensitivity to Dox. This increased sensitivity is particularly advantageous for in vivo studies in tissues where high Dox concentrations are difficult to attain (e.g., brain).
3. Tunable expression
Adjust expression to the level you need. Simply titrate Dox to the concentration that gives you the level of expression required for your experiment.
